<?xml version='1.0' encoding='utf-8'?>
<document id="31664782"><sentence text="Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug Interaction."><entity charOffset="0-12" id="DDI-PubMed.31664782.s1.e0" text="Itraconazole" /><entity charOffset="23-32" id="DDI-PubMed.31664782.s1.e1" text="Ibrutinib" /><pair ddi="false" e1="DDI-PubMed.31664782.s1.e0" e2="DDI-PubMed.31664782.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31664782.s1.e0" e2="DDI-PubMed.31664782.s1.e1" /></sentence><sentence text="The oral bioavailability of ibrutinib is low and variable, mainly due to extensive first-pass metabolism by cytochrome P450 (CYP) 3A4"><entity charOffset="28-37" id="DDI-PubMed.31664782.s2.e0" text="ibrutinib" /></sentence><sentence text=" The unpredictable exposure can compromise its safe and effective dosing" /><sentence text=" We examined the impact of itraconazole on ibrutinib pharmacokinetics"><entity charOffset="27-39" id="DDI-PubMed.31664782.s4.e0" text="itraconazole" /><entity charOffset="43-52" id="DDI-PubMed.31664782.s4.e1" text="ibrutinib" /><pair ddi="false" e1="DDI-PubMed.31664782.s4.e0" e2="DDI-PubMed.31664782.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31664782.s4.e0" e2="DDI-PubMed.31664782.s4.e1" /></sentence><sentence text=" In a randomized crossover study, 11 healthy subjects were administered itraconazole 200 mg or placebo twice on day 1, and once on days 2-4"><entity charOffset="72-84" id="DDI-PubMed.31664782.s5.e0" text="itraconazole" /></sentence><sentence text=" On day 3, 1 hour after itraconazole (placebo) and breakfast, ibrutinib (140 mg during placebo; 15 mg during itraconazole) was administered"><entity charOffset="24-36" id="DDI-PubMed.31664782.s6.e0" text="itraconazole" /><entity charOffset="62-71" id="DDI-PubMed.31664782.s6.e1" text="ibrutinib" /><entity charOffset="109-121" id="DDI-PubMed.31664782.s6.e2" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.31664782.s6.e0" e2="DDI-PubMed.31664782.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31664782.s6.e0" e2="DDI-PubMed.31664782.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31664782.s6.e0" e2="DDI-PubMed.31664782.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31664782.s6.e1" e2="DDI-PubMed.31664782.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31664782.s6.e1" e2="DDI-PubMed.31664782.s6.e2" /></sentence><sentence text=" Itraconazole increased the dose-adjusted geometric mean area under the concentration-time curve from zero to infinity (AUC0-∞ ) of ibrutinib 10"><entity charOffset="1-13" id="DDI-PubMed.31664782.s7.e0" text="Itraconazole" /><entity charOffset="132-141" id="DDI-PubMed.31664782.s7.e1" text="ibrutinib" /><pair ddi="false" e1="DDI-PubMed.31664782.s7.e0" e2="DDI-PubMed.31664782.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31664782.s7.e0" e2="DDI-PubMed.31664782.s7.e1" /></sentence><sentence text="0-fold (90% confidence interval (CI) 7" /><sentence text="2-13" /><sentence text="9; P &lt; 0" /><sentence text="001) and peak plasma concentration (Cmax ) 8" /><sentence text="8-fold (90% CI 6" /><sentence text="3-12" /><sentence text="1; P &lt; 0" /><sentence text="001)" /><sentence text=" During itraconazole, the intersubject variation for the AUC0-∞ (55%) and Cmax (53%) was around half of that during placebo (104%; 99%)"><entity charOffset="8-20" id="DDI-PubMed.31664782.s16.e0" text="itraconazole" /></sentence><sentence text=" In conclusion, itraconazole markedly increases ibrutinib bioavailability and decreases its interindividual variability, offering a possibility to improved dosing accuracy and cost savings"><entity charOffset="16-28" id="DDI-PubMed.31664782.s17.e0" text="itraconazole" /><entity charOffset="48-57" id="DDI-PubMed.31664782.s17.e1" text="ibrutinib" /><pair ddi="false" e1="DDI-PubMed.31664782.s17.e0" e2="DDI-PubMed.31664782.s17.e0" /><pair ddi="false" e1="DDI-PubMed.31664782.s17.e0" e2="DDI-PubMed.31664782.s17.e1" /></sentence><sentence text="" /></document>